Ovid Therapeutics Inc. Sample Contracts

OVID THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities
Indenture • November 3rd, 2023 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

INDENTURE, dated as of [•], 20 , among OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):

Sample 1Sample 2Sample 3See All (713)
AutoNDA by SimpleDocs
OVID THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF
Preferred Stock Warrant Agreement • November 3rd, 2023 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (429)
AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF
Common Stock Warrant Agreement • November 3rd, 2023 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (361)
AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF
Warrant Agreement • November 3rd, 2023 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (338)
OVID THERAPEUTICS INC. Common Stock (par value $0.001 per share) SALES AGREEMENT
Sales Agreement • November 13th, 2020 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

Ovid Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:

Sample 1Sample 2Sample 3See All (275)
6,250,000 Shares Ovid Therapeutics Inc. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • August 26th, 2020 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Sample 1Sample 2Sample 3See All (248)
OVID THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF
Warrant Agreement • November 13th, 2020 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (144)
INDEMNITY AGREEMENT
Indemnity Agreement • May 3rd, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • Delaware

THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement terminates any and all previous indemnification agreements entered into by and between the Company and the Indemnitee.

Sample 1Sample 2Sample 3See All (61)
OVID THERAPEUTICS INC.
Stock Option Agreement • April 10th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”).

Sample 1Sample 2Sample 3See All (55)
OVID THERAPEUTICS INC.
Stock Option Agreement • April 10th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement — Early Exercise (the “Option Agreement”).

Sample 1Sample 2Sample 3See All (19)
Ovid Therapeutics Inc. [•] Shares Common Stock ($0.001 par value) Underwriting Agreement
Underwriting Agreement • April 18th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

Ovid Therapeutics Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the contex

Sample 1Sample 2Sample 3See All (11)
OVID THERAPEUTICS INC.
Restricted Stock Purchase Agreement • April 10th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Restricted Stock Purchase Agreement (the “Agreement”).

Sample 1Sample 2Sample 3See All (10)
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • August 16th, 2021 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

Jeff Rona (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Chief Business Officer pursuant to the terms of an Executive Employment Agreement with the Company effective September 30, 2020 (the “Prior Agreement”). Executive and the Company hereby agree to this amended agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of June 2, 2021 (the “Effective Date”) and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain bolded terms used in this Agreement are defined in Section 6.

Sample 1Sample 2Sample 3See All (6)
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • May 8th, 2018 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

Matthew During (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its President and Chief Scientific Officer (“CSO”) pursuant to the terms of an Executive Employment Agreement with the Company dated June 5, 2015 (the “Prior Agreement”). Executive and the Company hereby agree to amend and restate the Prior Agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of the effective date of the first registration statement filed by the Company to register shares of its common stock for sale to the public through one or more underwriters (the “Effective Date”), and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain capitalized terms used in this Agreement are defined in Section 6.

Sample 1Sample 2Sample 3See All (5)
Contract
License Agreement • May 2nd, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Sample 1Sample 2
LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND OVID THERAPEUTICS INC. JANUARY 6, 2017
License and Collaboration Agreement • April 10th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

This License and Collaboration Agreement (this “Agreement”) is made effective as of January 6, 2017 (the “Effective Date”) by and between Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”) and Ovid Therapeutics Inc., a company incorporated under the laws of the State of Delaware having its principal place of business at 1460 Broadway, New York, NY 10036, U.S.A. (“Ovid”). Ovid and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Sample 1Sample 2
= Certain confidential information contained in this document, marked by brackets, is omitted because it is not material and would be competitively harmful if publicly disclosed.
License Agreement • June 17th, 2019 • Ovid Therapeutics Inc. • Pharmaceutical preparations

THIS FIRST AMENDMENT TO LICENSE AGREEMENT (this “Amendment”) is made as of this 10th day of May, 2019 (“Amendment Effective Date”), by and between Ovid Therapeutics Inc., with offices located at 1460 Broadway, Suite 15021, New York, NY 10036 (“Ovid”), and H. Lundbeck A/S, having a place of business located at Ottiliavej 9, DK 2500 Valby, Denmark (“Lundbeck”).

Sample 1Sample 2
Re: 3(a)(9) Exchange Agreement
3(a)(9) Exchange Agreement • September 19th, 2019 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

This letter agreement (the “Agreement”) confirms the agreement of Ovid Therapeutics Inc., a Delaware corporation (the “Company”), and the holders of the Common Stock listed on Schedule I attached hereto (the “Stockholders”), pursuant to which the Stockholders have agreed to exchange an aggregate of 1,262,000 shares (the “Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), beneficially owned by the Stockholders in consideration for a total of 1,262 shares of Series A Preferred Stock of the Company (the “Preferred Shares”), which shall have the rights, preferences and privileges set forth in the Amended and Restated Certificate of Designation set forth on Exhibit A attached hereto (the “COD”). The Preferred Shares will be convertible into a total of 1,262,000 shares of Common Stock (subject to adjustment as provided in the COD), subject to beneficial ownership conversion limitations set forth in the COD.

Sample 1
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
Investors’ Rights Agreement • February 3rd, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 6th day of January, 2017, by and among Ovid Therapeutics Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder.”

Sample 1
COLLABORATION AND LICENSE Agreement
Collaboration and License Agreement • November 13th, 2020 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

This Collaboration and License Agreement (the “Agreement”) is entered into as of July 8, 2020 (the “Effective Date”), by and between Ovid Therapeutics Inc., a Delaware company having an address at 1460 Broadway, Suite 15021 New York, NY 10036, USA (“Ovid”) and Angelini Pharma Rare Diseases AG, a Swiss company under direction and control of Angelini Pharma S.p.A. and having an address at Consulting GmbH Sumpfstrasse 26 6312 Steinhausen, Zurich, Switzerland (“Licensee”). Ovid and Licensee may be referred to herein individually as a “Party” or collectively as the “Parties”.

Sample 1
LICENSE AGREEMENT between ASTRAZENECA AB and OVID THERAPEUTICS INC. Dated as of December 30, 2021
License Agreement • January 3rd, 2022 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

This License Agreement (this “Agreement”) is made and entered into effective as of December 30, 2021 (the “Effective Date”) by and between AstraZeneca AB, a company incorporated in Sweden under No. 556011-7482, whose registered office is registered at SE-151 85 Södertälje, Sweden and with offices at SE-431 83 Mölndal, Sweden (“AstraZeneca”) and Ovid Therapeutics Inc., a Delaware corporation having its principal place of business at Suite 15044, 1460 Broadway, New York, NY 10036 U.S.A. (“Licensee”). AstraZeneca and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Sample 1
SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENT
Preferred Stock Purchase Agreement • April 10th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

THIS SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 6th day of January, 2017 by and among Ovid Therapeutics Inc., a Delaware corporation (the “Company”), and Takeda Pharmaceutical Company Limited (the “Purchaser”).

Sample 1
AutoNDA by SimpleDocs
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
Royalty Agreement • October 18th, 2023 • Ovid Therapeutics Inc. • Pharmaceutical preparations

Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously retaining 87% of the interest in soticlestat

Sample 1
SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENT
Series B-1 Preferred Stock Purchase Agreement • March 20th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

THIS SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 6th day of January, 2017 by and among Ovid Therapeutics Inc., a Delaware corporation (the “Company”), and Takeda Pharmaceutical Company Limited (the “Purchaser”).

Sample 1
Contract
Purchase and Sale Agreement • March 8th, 2024 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Sample 1
= Certain confidential information contained in this document, marked by brackets, is omitted because it is not material and would be competitively harmful if publicly disclosed.
Separation and Consulting Agreement • May 7th, 2019 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Ovid Therapeutics Inc. (the “Company”) is offering to you.

Sample 1
Contract
License Agreement • May 14th, 2024 • Ovid Therapeutics Inc. • Pharmaceutical preparations
Sample 1
LICENSE AGREEMENT
License Agreement • March 29th, 2018 • Ovid Therapeutics Inc. • Pharmaceutical preparations

This License Agreement (“Agreement”) made this 15th day of December, 2016 (the “Effective Date”) by and between Northwestern University, an Illinois corporation having a principal office at 633 Clark Street, Evanston, Illinois 60208 (hereinafter referred to as “Northwestern”) and Ovid Therapeutics, a Delaware corporation having a principal office at 1460 Broadway, Suite 15044, New York, NY 10036 (hereinafter referred to as “Licensee”).

Sample 1
COLLABORATION AND LICENSE Agreement
Collaboration and License Agreement • March 15th, 2021 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

This Collaboration and License Agreement (the “Agreement”) is entered into as of July 8, 2020 (the “Effective Date”), by and between Ovid Therapeutics Inc., a Delaware company having an address at 1460 Broadway, Suite 15021 New York, NY 10036, USA (“Ovid”) and Angelini Pharma Rare Diseases AG, a Swiss company under direction and control of Angelini Pharma S.p.A. and having an address at Consulting GmbH Sumpfstrasse 26 6312 Steinhausen, Zurich, Switzerland (“Licensee”). Ovid and Licensee may be referred to herein individually as a “Party” or collectively as the “Parties”.

Sample 1
ROYALTY, LICENSE AND TERMINATION AGREEMENT RELATING TO LICENSE AND COLLABORATION AGREEMENT DATED JANUARY 6, 2017 BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND OVID THERAPEUTICS INC. MARCH 2, 2021
Royalty, License and Termination Agreement • May 13th, 2021 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York

This Royalty, License and Termination Agreement (this “Agreement”) is made effective as of March 2, 2021 (the “Effective Date”) by and between Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”), and Ovid Therapeutics Inc., a company incorporated under the laws of the State of Delaware having its principal place of business at 1460 Broadway, New York, NY 10036, U.S.A. (“Ovid”). Ovid and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Sample 1
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!